Zobrazeno 1 - 10
of 322
pro vyhledávání: '"Hamnvik OR"'
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-7 (2024)
Abstract Background Natalizumab is a monoclonal antibody used to treat patients with relapsing–remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when natalizumab is stopped. Here, we de
Externí odkaz:
https://doaj.org/article/fc2cecd946034d73a262b7b311f3683b
Autor:
Rothman, Micol S., Ariel, Danit, Kelley, Carly, Hamnvik, Ole-Petter R., Abramowitz, Jessica, Irwig, Michael S., Soe, Kyaw, Davidge-Pitts, Caroline, Misakian, Aaron L., Safer, Joshua D., Iwamoto, Sean J.
Publikováno v:
In Endocrine Practice September 2024 30(9):870-878
Autor:
Lucia Kwak, So Yeon Kim, Guru Sonpavde, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Rana R McKay, Toni K Choueiri, Thomas Marron, Amin H Nassar, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Ahmad Al-Hader, Edward El-Am, Dory Freeman, Ahmed Bilal Khalid, Marita Salame, Elias Bou Farhat, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Talal El Zarif, Serena Rahme, Caiwei Zhong, Tarek H Mouhieddine
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce.Methods In this retrospective s
Externí odkaz:
https://doaj.org/article/e3a36a44dc60429b90c5ae6bfb360660
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia July 2024
Autor:
Hamnvik, Lars Henrik Dahl1,2 (AUTHOR) lahdah@vestreviken.no, Tjønnfjord, Geir E.2,3 (AUTHOR), Spetalen, Signe4 (AUTHOR), Dalgaard, Jakob1 (AUTHOR)
Publikováno v:
Journal of Medical Case Reports. 5/13/2024, Vol. 18 Issue 1, p1-7. 7p.
Autor:
Lucia Kwak, So Yeon Kim, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Toni K Choueiri, Rana Mckay, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Amin Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena J Rahme, Marita Salame, Elias Bou Farhat, Edward El Am, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Guru P Sonpavde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/df99a0c739d64783afe5458e630339d9
Publikováno v:
International Journal of Women's Health, Vol Volume 15, Pp 1-6 (2023)
Thomas Larsen Titze,1 Lars Henrik Dahl Hamnvik,2 Inga Marie Hauglum,1 Anne Elisabeth Tonay Carlsen,2 Lena Tjeldhorn,3 Nhan Trung Nguyen,3 Çiğdem Akalın Akkök3 1Department of Laboratory Medicine, Vestre Viken Health Trust, Drammen, Norway; 2Depart
Externí odkaz:
https://doaj.org/article/ae0dc044a3c14d649c79794ee6d7fece
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paolo Zanaboni, Unn Sollid Manskow, Edvard Hamnvik Sagelv, Bente Morseth, Alf Egil Edvardsen, Inger-Lise Aamot, Bjarne Martens Nes, Bryce Hastings, Marie-Pierre Gagnon, Konstantinos Antypas
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
IntroductionPhysical inactivity is the fourth leading risk factor for global mortality, and inactive adults have a higher risk to develop lifestyle diseases. To date, there is preliminary evidence of the efficacy of fitness technologies and other dig
Externí odkaz:
https://doaj.org/article/182c0bf69db54e54b4691b84ab4ef7c4